Comparison of Symbicort® versus Pulmicort® on steroid pharmacodynamic markers in asthma patients

Autor: Kazuhiro Ito, Sergei A. Kharitonov, Misako Ito, Peter J. Barnes, Sarah Essilfie-Quaye
Rok vydání: 2011
Předmět:
Zdroj: Respiratory Medicine. 105:1784-1789
ISSN: 0954-6111
0015-9263
DOI: 10.1016/j.rmed.2011.08.020
Popis: SummaryBackgroundCombination therapy with inhaled corticosteroids (ICS) and long-acting β2-adrenergic agonists (LABA) is reported to have superior effects on controlling asthma symptoms to ICS alone; however, there is no molecular-based evidence to explain the clinical effects. Here, the effect of the ICS/LABA combination was compared with ICS on glucocorticoid receptor (GR) activation in sputum macrophages.MethodsIn a randomised, double-blind cross-over placebo-controlled 6-visit study, 10 patients with mild asthma were given placebo, formoterol (Oxis® 12 μg), budesonide (Pulmicort® 200 μg :BUD200, or 800 μg :BUD800), or budesonide/formoterol combination (Symbicort®) as a single 100/6 μg (SYM100) or double 200/12 μg (SYM200) dose. Sputum macrophages were separated by plate adhesion from induced sputum. GR binding to the glucocorticoid-response elements on oligonucleotides (GR-GRE binding) was evaluated by ELISA. mRNA expression of MAP-kinase phosphatase (MKP)-1 and IL-8 were measured by quantitative RT-PCR.ResultsGR-GRE binding was significantly increased after treatment with SYM100 (3.5 OD/10 μg protein, median, p
Databáze: OpenAIRE